Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dose-finding trial of OPC-34712 (brexpiprazole) in acute schizophrenia
jRCT2080221591Phase 3Completed
- Sponsor
- Otsuka Pharmaceutical Co., Ltd.
- Start
- Sep 2011
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of brexpiprazole in schizophrenia (4 arms), sponsored by Otsuka Pharmaceutical Co., Ltd. Primary endpoint: Efficacy in acute schizophrenia. Started Sep 2011; status: completed.
02
Drugs
brexpiprazole
03
Conditions
schizophrenia
Beyond the preview
Go deeper on jRCT2080221591.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080221591.